Premium
Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML 99 protocol in the period 2003–06 from the J apan Association of Childhood Leukaemia Study
Author(s) -
Imamura Toshihiko,
Iwamoto Shotaro,
Kanai Rie,
Shimada Akira,
Terui Kiminori,
Osugi Yuko,
Kobayashi Ryoji,
Tawa Akio,
Kosaka Yoshiyuki,
Kato Koji,
Hori Hiroki,
Horibe Keizo,
Oda Megumi,
Adachi Souichi
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12030
Subject(s) - medicine , cohort , myeloid leukaemia , clinical trial , myeloid , hematopoietic stem cell transplantation , transplantation , cohort study , oncology , pediatrics
Summary The acute myeloid leukaemia ( AML ) 99 trial conducted previously in J apan for the treatment of de novo paediatric AML showed excellent results, with a 5‐year overall survival ( OS ) and event‐free survival ( EFS ) of 75·6% and 61·6%, respectively. To examine reproducibility of these results in another cohort, the outcome of 146 newly diagnosed AML paediatric patients prospectively registered in the J apan Association of Childhood Leukaemia Study ( JACLS ) from 2003 to 2006 was compared to that of 240 patients in the original AML 99 clinical trial. The 5‐year EFS and OS achieved in the new cohort was 66·7 ± 4·0% and 77·7 ± 8·0% respectively, which were comparable to those obtained in the original AML 99 clinical trial, although less frequent core‐binding factor ( CBF ) AML (29·5% vs. 37%) and an almost equal frequency of allogeneic haematopoietic stem cell transplantation (allo‐ HSCT ) during first complete remission (16·5% vs. 19%) were observed. The 5‐year EFS in patients with a normal karyotype ( NK ) ( n = 35, 54·9 ± 15·1%) was inferior in the present cohort when compared to the original AML 99 trial. This study confirmed the excellent outcome of the original AML 99 protocol.